Develop drugs in children first when the target is a children's target
Children wait years for drugs because adult trials come first, even when the target belongs to a childhood cancer. Some drugs should start with children.
Paediatric oncology drug development is usually a downstream obligation, with paediatric plans triggered by adult programmes. For fusion-driven and developmental-lineage targets such as ALK in neuroblastoma, NTRK fusions, H3K27M-altered glioma and specific sarcoma fusions, the disease biology is paediatric and adult data add little. A paediatric-first pathway with matched incentives would compress timelines by years.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaEscrow a share of adult revenue until the paediatric study is done
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Incentives reward me-too drugs and marginal gains, Rare and paediatric cancers without markets.
- IdeaAdvance market commitments for paediatric and rare cancer drugs
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Incentives reward me-too drugs and marginal gains, Rare and paediatric cancers without markets.
- InstitutionChildren's Cancer Hospital Egypt 57357
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST), Acute lymphoblastic leukaemia.
- InstitutionSIOP Europe – European Society for Paediatric Oncology
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- InstitutionChildren's Cancer and Leukaemia Group
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST), Acute lymphoblastic leukaemia.
- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Regulatory divergence between regions, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
- InstitutionSydney Children's Hospitals Network / Children's Cancer Institute
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Sarcomas (soft tissue, bone, GIST), Acute lymphoblastic leukaemia.